首页> 外文期刊>Vaccine >Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine
【24h】

Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine

机译:使用泰国红十字会皮内注射的狂犬病疫苗的效力要求:连续稀释的纯化鸡胚细胞狂犬病疫苗的免疫原性调查

获取原文
获取原文并翻译 | 示例
       

摘要

To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen.
机译:为了确定使用泰国红十字会(TRC)方案(2-2-2-0-1-1)引起充分免疫应答所需的每皮内剂量的最低疫苗效力,健康志愿者接受0.1毫升体积减少的PCECV抗原。受试者还接受了HRIG评估抗体生产的潜在干扰。结果表明,当每0.1 mL皮内注射PCECV含有对应于每肌内剂量0.32 IU的抗原时,每个受试者在第14天的滴度都超过0.5 IU / mL。这些结果证实了当前世界卫生组织(WHO)关于疫苗效力的建议(每肌肉注射2.5 IU)足以用于泰国红十字会的皮内治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号